+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Risk factors for relapse in patients with clinical stage I testicular nonseminomatous germ cell tumors



Risk factors for relapse in patients with clinical stage I testicular nonseminomatous germ cell tumors



Medical Oncology 30(1): 494



Prediction of oncological outcomes facilitates individualized risk-adapted management for clinical stage I testicular nonseminomatous germ cell tumors (CS I NSGCTs). We investigated risk factors for relapse following orchidectomy, with particular focus on patients with active surveillance. Patients with CS I NSGCTs treated by retroperitoneal lymph node dissection (RPLND), chemotherapy, or surveillance between January 1997 and December 2009 were identified. Demographic and post-operative records were collected. Disease-specific survival and progression-free survival (PFS) rates were estimated using Kaplan-Meier analysis. Cox regression analysis was used to confirm variables that influenced disease relapse. A median follow-up period of 82 months was achieved in 89 patients, of whom 9 (8 in surveillance and 1 in chemotherapy group) had relapses. Cumulative 5-year PFS rates were 74.1, 92.3, and 100 % for the surveillance, chemotherapy, and RPLND groups, respectively (p = 0.01). The relapse rate was significantly higher in patients presented with lymphatic/vascular invasion (LVI) than in those without LVI (26.6 vs. 6.8 %, p = 0.02). In the surveillance group, a higher relapse rate was associated with history of cryptorchidism (50 vs. 13.3 %, p = 0.02) and an age older than 13 years (33.3 vs. 5.9 %, p = 0.04). On multivariate analysis, patient age (OR 1.16; p = 0.05), history of cryptorchidism (OR 0.09; p = 0.01), and LVI (OR 12.10; p = 0.01) were significantly associated with relapse during surveillance. The disease-free period is short in the patients with surveillance. LVI, patient age, and history of cryptorchidism may be used as predictors for relapse during surveillance.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036762784

Download citation: RISBibTeXText

PMID: 23400963

DOI: 10.1007/s12032-013-0494-y


Related references

Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. Journal of Clinical Oncology 21(8): 1505-1512, 2003

Serum lactate dehydrogenase isoenzyme 1 and relapse in patients with nonseminomatous testicular germ cell tumors clinical stage I. Acta Oncologica 40(4): 536-540, 2001

Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. Journal of Urology 161(4): 1148-1152, 1999

Is retroperitoneal lymph node dissection alone optimal or sufficient therapy for clinical stage I nonseminomatous germ cell testicular tumors at high risk for relapse?. Journal of Urology 159(5 Suppl. ): 49, 1998

Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: rationale for different risk-adapted treatment. European Urology 33(6): 562-566, 1998

MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis. Cancer. 79(9): 1710-1716, 1997

MIB-1 Immunohistochemistry in Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors Predicts Patients at Low Risk for Metastasis. Journal of Urology 160(6): 2291-2292, 1998

Clinical stage 1 nonseminomatous germ cell tumors of the testis nsgctt managed by surveillance identification of patients with low risk of relapse. Journal of Urology 141(4 Part 2): 302A, 1989

Histopathological and biological prognostic risk factors in low stage testicular nonseminomatous germ cell tumors. Urologe Ausgabe A 38(2): 168-178, 1999

Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 83(5): 1002-1011, 1998

Surveillance for patients with clinical stage I nonseminomatous testicular germ cell tumors. World Journal of Urology 33(9): 1351-1357, 2015

Conditional risk of relapse in patients with germ cell testicular tumors: personalizing surveillance in clinical stage 1 disease. Current Opinion in Urology 28(5): 454-460, 2018

The case for observation of patients with clinical stage I nonseminomatous germ cell testicular tumors. Seminars in Urology 11(2): 92-98, 1993

Risk Stratification of Pubertal Children and Postpubertal Adolescents with Clinical Stage I Testicular Nonseminomatous Germ Cell Tumors. Yearbook of Urology 2014: 285-286, 2014

Risk stratification of pubertal children and postpubertal adolescents with clinical stage I testicular nonseminomatous germ cell tumors. Journal of Urology 191(5 Suppl): 1485-1490, 2014